Presbyopia awareness: A deep dive with Brieann Adair, OD

Video

Presbyopia awareness: Causes, risk factors, symptoms, correction options and market trends.

Current Time 0:00
Duration 9:52
Loaded: 1.66%
Stream Type LIVE
Remaining Time 9:52
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    In celebration of Presbyopia Awareness Month, Brieann K. Adair, OD, of NYU Langone Health, speaks with Optometry Times' Sheryl Stevenson about the importance of Presbyopia awareness, causes of the condition, risk factors, symptoms, correction options and market trends.

    Newsletter

    Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

    Subscribe Now!
    Recent Videos
    Susana Marcos, PhD, outlines a presentation she gave at ARVO 2025 on a unique utilization of optical coherence tomography.
    ARVO 2025: OCT-based marker for accommodative effort in presbyopes
    AnnMarie Hipsley, DPT, PhD, at ASCRS 2025
    Predicting presbyopia reading ADD and progression with AI and machine learning algorithm
    Neda Shamie, MD; Selina McGee, OD, FAAO, Dipl ABO; and Jacob Lang, OD, FAAO; provided their insights during CIME 2025 on May 4.
    CIME 2025: What you missed in presbyopia tips, tricks, and updates
    Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
    CIME 2025: Exploring pharmacological options for presbyopia correction with Selina McGee, OD, FAAO
    CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
    CIME 25: Dilsher Dhoot, MD, FASRS, excited about emerging retinal therapies
    Dr Jacob Lang at the 2025 Controversies in Modern Eye Care meeting
    CIME 2025: Pharmacologic presbyopia correction provides new hope for flexibility for patients
    At ASCRS 2025, Alex Hacopian, MD, shares information from his presentation on next-gen presbyopia-correcting intraocular lenses.
    ASCRS 2025: Enhancing patient outcomes with presbyopia-correcting IOLs
    Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
    Inside the MOA of SYD-101, the potential first FDA-approved formulation of low-dose atropine
    OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
    OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
    Dr. Mile Brujic discusses a case series on a novel gel for lacrimal occlusion.
    SECO 2025: A novel gel may work better than punctal plugs for lacrimal occlusion
    Related Content
    FDA approves Alcon’s Tryptyr (AR-15512) for signs and symptoms of dry eye disease

    FDA approves Alcon’s Tryptyr (AR-15512) for signs and symptoms of dry eye disease

    Emily Kaiser Maharjan, Assistant Managing Editor;Martin David Harp, Editor, Ophthalmology Times
    May 29th 2025
    Article
    Practical management EP 14: Your practice-purchase checklist

    Practical management EP 14: Your practice-purchase checklist

    Maria Sampalis, OD;Kassi Filkins, Editor
    April 27th 2023
    Podcast
    Nicox releases results from Whistler phase 3b trial in IOP-lowering drops - Image credit: ©Jo Panuwat D—stock.adobe.com

    Nicox releases results from Whistler phase 3b trial in IOP-lowering eye drops

    Martin David Harp, Editor, Ophthalmology Times
    May 16th 2025
    Article
    Jill Saxon, OD, executive director of professional strategy at Bausch + Lomb

    Community care: Connecting mentorship and representation

    Emily Kaiser Maharjan, Assistant Managing Editor
    April 26th 2023
    Podcast
    Boehringer advances 2 geographic atrophy candidates to phase 2 clinical trials - Image credit: ©Dzmitry—stock.adobe.com

    Boehringer Ingelheim kicks off dual phase 2 clinical studies for geographic atrophy candidates

    Emily Kaiser Maharjan, Assistant Managing Editor
    May 8th 2025
    Article
    Luminopia's ambloyopia treatment now covered by Anthem Blue Cross Blue Shield. - Image credit: ©WavebreakMediaMicro—stock.adobe.com

    Anthem Blue Cross Blue Shield approves coverage for amblyopia treatment from Luminopia

    Emily Kaiser Maharjan, Assistant Managing Editor
    May 8th 2025
    Article
    © 2025 MJH Life Sciences

    All rights reserved.